Back to search

Article

Chiaurinib Selectively Inhibits Colorectal Cancer with KRAS Wild-Type by Modulation of ROS through Activating the p53 Signaling Pathway

2020-07-23

Abstract excerpt

<h4>Background: </h4> Colorectal cancer (CRC) is one of the top three most deadly cancers despite using chemotherapy based on oxaliplatin or irinotecan combined with targeted therapy. Chiaurinib has recently been identified to be a promising anticancer candidate with impressive efficacy and safety. However, the role and molecular mechanisms of Chiaurinib in the treatment of CRC remain to be elucidated. <h4>Methods...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
62d3657a-4981-59d8-961f-f478bd45fbc8
DOI
10.21203/rs.3.rs-46779/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Chiaurinib Selectively Inhibits Colorectal Cancer with KRAS Wild-Type by Modulation of ROS through Activating the p53 Signaling PathwayDOI 10.21203/rs.3.rs-46779/v1
Select a neighboring publication to make it the new centre.